Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Vittore Cereda, Vincenzo Formica & Mario Roselli. (2018) Issues and promises of bevacizumab in prostate cancer treatment. Expert Opinion on Biological Therapy 18:6, pages 707-717.
Read now
Read now
. (2015) 3rd Mediterranean Multidisciplinary Course on Iron Anemia. Expert Review of Hematology 8:sup1, pages S1-S32.
Read now
Read now
Jonathan W. Riess, Aaron C. Logan, Yelena Krupitskaya, Sukhmani Padda, Christelle Clément-Duchêne, Kristen Ganjoo, A. Dimitrios Colevas, Melanie San Pedro-Salcedo, Calvin J. Kuo & Heather A. Wakelee. (2012) Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer. Cancer Investigation 30:3, pages 231-235.
Read now
Read now
Articles from other publishers (9)
Abhishek Tripathi, Susanna Jacobus, Hope Feldman, Toni K. Choueiri & Lauren C. Harshman. (2017) Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF-directed Therapy. Clinical Genitourinary Cancer 15:3, pages 396-402.
Crossref
Crossref
Omar Abdel-Rahman & Hesham ElHalawani. (2015) Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis. Future Oncology 11:21, pages 2949-2961.
Crossref
Crossref
Fariba Ahmadizar, N. Charlotte Onland-Moret, Anthonius de Boer, Geoffrey Liu & Anke H. Maitland-van der Zee. (2015) Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLOS ONE 10:9, pages e0136324.
Crossref
Crossref
Zuo-Pei Wang, Hai-Feng Zhang, Feng Zhang, Bao-Li Hu, Hai-Tao Wei & Yong-Yuan Guo. (2015) Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis. European Journal of Clinical Pharmacology 71:5, pages 517-524.
Crossref
Crossref
H Chen, M R Modiano, J W Neal, J R Brahmer, J R Rigas, R M Jotte, N B Leighl, J W Riess, C J Kuo, L Liu, B Gao, A T DiCioccio, A A Adjei & H A Wakelee. (2013) A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. British Journal of Cancer 110:3, pages 602-608.
Crossref
Crossref
Sumita S. Bhatta, Kristen E. Wroblewski, Kelly L. Agarwal, Laura Sit, Ezra E.W. Cohen, Tanguy Y. Seiwert, Theodore Karrison, George L. Bakris, Mark J. Ratain, Everett E. Vokes & Michael L. Maitland. (2013) Effects of Vascular Endothelial Growth Factor Signaling Inhibition on Human Erythropoiesis. The Oncologist 18:8, pages 965-970.
Crossref
Crossref
Nina N. Grenon. (2013) Managing Toxicities Associated With Antiangiogenic Biologic Agents in Combination With Chemotherapy for Metastatic Colorectal Cancer. Clinical Journal of Oncology Nursing 17:4, pages 425-433.
Crossref
Crossref
Camelia Iancu-Rubin, Goar Mosoyan, Jiapeng Wang, Thomas Kraus, Victoria Sung & Ronald Hoffman. (2013) Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Experimental Hematology 41:2, pages 155-166.e17.
Crossref
Crossref
J.-C. Soria, A. Mauguen, M. Reck, A.B. Sandler, N. Saijo, D.H. Johnson, D. Burcoveanu, M. Fukuoka, B. Besse & J.-P. Pignon. (2013) Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Annals of Oncology 24:1, pages 20-30.
Crossref
Crossref